This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2018
  • /
  • 06
  • /
  • Real world data shows treatment advantages of Trul...
Drug news

Real world data shows treatment advantages of Trulicity over once-daily liraglutide and once-weekly exenatide QW for type 2 diabetes, Eli Lilly.

Read time: 1 mins
Last updated:26th Jun 2018
Published:25th Jun 2018
Source: Pharmawand

People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity (dulaglutide) compared to once-daily liraglutide and once-weekly exenatide QW according to real-world data. These data are being presented at the American Diabetes Association's (ADA) 78th Scientific Sessions in Orlando.

Trulicity is Eli Lilly and Company's once-weekly, injectable GLP-1 RA approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity is available in 0.75 mg and 1.5 mg and should be used along with diet and exercise. Qing Huang, PhD, associate director and principal investigator from HealthCore, Inc,.stated "These real-world data show that people starting on once-weekly Trulicity are associated with a higher likelihood of adhering to their treatment regimen and having a lower A1C compared to two other GLP-1 RA options.",/p>

The retrospective observational study used U.S. claims data of people with type 2 diabetes newly prescribed Trulicity or either liraglutide or exenatide QW to compare how these treatments performed in a real-world setting. People were matched against key characteristics such as age, gender, location and baseline A1C to ensure balance in comparing the groups. Trulicity consistently showed advantages across all measures, including A1C reductions, adherence (taking treatment as prescribed) and persistence (staying on treatment). After both six months and one year of treatment, Trulicity provided significantly better glycemic control than liraglutide (mean absolute reduction in A1C in percent): Six months: -1.10 percent (Trulicity), -0.86 percent (liraglutide). One year: -0.98 percent (Trulicity), -0.77 percent (liraglutide). After six months and one year of treatment, Trulicity led to better glycemic control than exenatide QW (mean absolute reduction in A1C in percent): Six months: -1.15 percent (Trulicity), -0.92 percent (exenatide QW). One year: -1.00 percent (Trulicity), -0.77 percent (exenatide QW).

After one year, people taking Trulicity were significantly more likely to follow their treatment regimen and less likely to discontinue treatment than with liraglutide or exenatide QW. People taking Trulicity had significantly lower rates of discontinuing treatment than those taking liraglutide or exenatide QW.

Trulicity vs. liraglutide: Adherence: 51.2 percent (Trulicity), 38.2 percent (liraglutide). Persistence: 252.8 days (Trulicity), 218.2 days (liraglutide). Patients who discontinued treatment: 45.0 percent (Trulicity), 56.2 percent (liraglutide).

Trulicity vs. exenatide QW : Adherence: 50.7 percent (Trulicity), 31.9 percent (exenatide QW). Persistence: 251.4 days (Trulicity), 192.5 days (exenatide QW). Patients who discontinued treatment: 45.1 percent (Trulicity), 65.6 percent (exenatide QW).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.